Skip to main content
. 2022 Mar 5;45:101328. doi: 10.1016/j.eclinm.2022.101328

Table 1.

Regression analyses examining factors associated with prevalent TB disease in people living with HIV.

No prevalent TB, n (%) or median (IQR) N = 834 Prevalent TB, n (%) or median (IQR) N = 17 Univariable logistic regression
Multivariable binomial LASSO regression with selective inference
OR (95%CI) p value aOR (95%CI) p value
Sex
 Female 608 (72·9) 9 (52·9) Reference Reference
 Male 226 (27·1) 8 (47·1) 2·39 (0·89, 6·33) 0·076 1·34 (0·08, 2·88) 0·58
Age 35 (29–42) 36 (33–42) 1·02 (0·97, 1·08) 0·39 1·29 (0·00, 2·17) 0·77
Ethnicity
 Black African 704 (84·4) 12 (70·6) Reference
 Mixed Ancestry 130 (15·6) 5 (29·4) 2·26 (0·71, 6·19) 0·13
Site <0·001
 Durban, KwaZulu-Natal 288 (34·5) 7 (41·2) Reference 4·59 (1·49, 10·74) 0·006
 Klerksdorp, North West 160 (19·2) 0 (0·0) NA NA
 Rustenburg, North West 158 (18·9) 0 (0·0) NA NA
 Ravensmead, Western Cape 89 (10·7) 0 (0·0) NA NA
 Worcester, Western Cape 139 (16·7) 10 (58·8) 2·96 (1·11, 8·31) 0·031 5·08 (0·67, 10·63) 0·051
Highest level of schooling
 Primary school or lower 100 (12·0) 0 (0·0) NA Reference
 Secondary school or higher 734 (88·0) 17 (100·0) NA 2·29 (0·54, 7·66) 0·11
Employment
 Employed 131 (15·7) 3 (17·6) Reference
 Unemployed 703 (84·3) 14 (82·4) 0·87 (0·28, 3·81) 0·83
Occupants per household 4 (3–6) 4 (1–6) 0·87 (0·69, 1·04) 0·17 0·83 (0·27, 26·81) 0·65
Smoking history
 No 513 (61·5) 9 (52·9) Reference Reference
 Yes 321 (38·5) 8 (47·1) 1·42 (0·53, 3·75) 0·47 0·60 (0·31, 17·78) 0·52
Prior TB
 No 630 (75·5) 13 (76·5) Reference Reference
 Yes 204 (24·5) 4 (23·5) 0·95 (0·27, 2·72) 0·93 0·75 (0·50, 78·17) 0·73
TB household contacts
 No 674 (80·8) 17 (100·0) NA Reference
 Yes 160 (19·2) 0 (0·0) NA 0·35 (0·13, 1·61) 0·076
Isoniazid preventive therapy at enrolment
 Not on therapy 788 (94·5) 17 (100·0) NA
 On therapy 46 (5·5) 0 (0·0) NA
Antiretroviral therapy at enrolment 0·21
 Naïve 183 (21·9) 7 (41·2) Reference 1·13 (0·03, 1·73) 0·77
 <6 months 112 (13·4) 2 (11·8) 0·47 (0·07, 1·97) 0·35
 ≥6 months 539 (64·6) 8 (47·1) 0·39 (0·14, 1·12) 0·071
Body-mass index (kg/m2) 24·3 (20·6–31·3) 21·3 (18·7–24·0) 0·90 (0·81, 0·98) 0·028 0·33 (0·10, 1·67) 0·078
CD4-positive cell count (cells/mm3) 530·5 (354·2–731·0) 393·0 (248·0–591·0) 0·89 (0·80, 0·98) * 0·028 0·62 (0·20, 1·71) * 0·15
HIV plasma viral load
 <100 copies/mL 179 (45·1) 1 (9·1) Reference # #
 ≥100 copies/mL 218 (54·9) 10 (90·9) 8·21 (1·55, 151·41) 0·046
 Not tested (missing) 437 6 NA NA
Season at enrolment 0·17
 Spring 196 (23·5) 8 (47·1) Reference 1·41 (0·66, 196·86) 0·081
 Summer 218 (26·1) 2 (11·8) 0·22 (0·03, 0·91) 0·061
 Autumn 188 (22·5) 3 (17·6) 0·39 (0·08, 1·37) 0·17
 Winter 232 (27·8) 4 (23·5) 0·42 (0·11, 1·36) 0·16 0·85 (0·58, >1000) 0·88
TB symptoms at enrolment
 No 789 (94·6) 15 (88·2) Reference Reference
 Yes 45 (5·4) 2 (11·8) 2·34 (0·36, 8·63) 0·27 1·18 (0·04, 2·11) 0·72
IGRA status
 Negative 455 (54·6) 5 (29·4) Reference Reference
 Positive 379 (45·4) 12 (70·6) 2·88 (1·06, 9·12) 0·049 1·63 (0·62, 3·20) 0·14

IQR, interquartile range. CI, confidence interval. OR, odds ratio. aOR, adjusted OR. IGRA, interferon-γ release assay. TB, tuberculosis. NA, not applicable. *Per 50 cells/mm3. #Excluded from LASSO analysis. Reference group includes all other levels of variable. Likelihood-ratio test for significance of categorical variable.